Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week Low After Analyst Downgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reached a new 52-week low on Friday after Wells Fargo & Company lowered their price target on the stock from $1,050.00 to $900.00. Wells Fargo & Company currently has an overweight rating on the stock. Regeneron Pharmaceuticals traded as low as $691.00 and last traded at $698.34, with a volume of 492017 shares. The stock had previously closed at $733.59.

Several other equities analysts also recently weighed in on REGN. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Royal Bank of Canada lowered their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Barclays reduced their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Finally, Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target for the company. One investment analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $1,037.33.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp raised its stake in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after purchasing an additional 61,277 shares during the last quarter. International Assets Investment Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after acquiring an additional 879,916 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after acquiring an additional 11,499 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Regeneron Pharmaceuticals by 12.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock worth $567,864,000 after acquiring an additional 59,769 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in Regeneron Pharmaceuticals by 0.7% during the second quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock worth $357,945,000 after purchasing an additional 2,270 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

The stock’s 50-day moving average is $754.37 and its 200 day moving average is $965.13. The stock has a market cap of $76.70 billion, a price-to-earnings ratio of 17.27, a P/E/G ratio of 2.19 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.